Lyell Immunopharma annual net debt
2020
2021
2022
2023
2024
2025
Lyell Immunopharma Net Debt Growth & History (LYEL)
Lyell Immunopharma's net debt was −$9.2M for fiscal 2025.
View full Lyell Immunopharma company overviewLyell Immunopharma annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$9.2M | $37.4M | — |
| 2024 | 2024-12-31 | −$46.6M | $35.9M | — |
| 2023 | 2023-12-31 | −$82.5M | −$26.6M | — |
| 2022 | 2022-12-31 | −$55.9M | $170.2M | — |
| 2021 | 2021-12-31 | −$226.0M | −$140.2M | — |
| 2020 | 2020-12-31 | −$85.8M | — | — |
Lyell Immunopharma quarterly net debt
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$26.4M | $17.3M | — |
| Q1 2026 | 2026-03-31 | −$41.9M | $21.3M | — |
| Q4 2025 | 2025-12-31 | −$9.2M | $37.4M | — |
| Q3 2025 | 2025-09-30 | −$70.5M | −$28.8M | — |
| Q2 2025 | 2025-06-30 | −$43.7M | $29.5M | — |
| Q1 2025 | 2025-03-31 | −$63.2M | $585,000 | — |
| Q4 2024 | 2024-12-31 | −$46.6M | $35.9M | — |
| Q3 2024 | 2024-09-30 | −$41.7M | $179.9M | — |
| Q2 2024 | 2024-06-30 | −$73.2M | $85.1M | — |
| Q1 2024 | 2024-03-31 | −$63.8M | −$21.0M | — |
| Q4 2023 | 2023-12-31 | −$82.5M | −$26.6M | — |
| Q3 2023 | 2023-09-30 | −$221.6M | −$172.7M | — |
| Q2 2023 | 2023-06-30 | −$158.3M | −$20.1M | — |
| Q1 2023 | 2023-03-31 | −$42.8M | $111.0M | — |
| Q4 2022 | 2022-12-31 | −$55.9M | $170.2M | — |
| Q3 2022 | 2022-09-30 | −$48.8M | $277.4M | — |
| Q2 2022 | 2022-06-30 | −$138.2M | $362.8M | — |
| Q1 2022 | 2022-03-31 | −$153.8M | — | — |
| Q4 2021 | 2021-12-31 | −$226.0M | −$140.2M | — |
| Q3 2021 | 2021-09-30 | −$326.3M | — | — |
| Q2 2021 | 2021-06-30 | −$501.0M | — | — |
| Q4 2020 | 2020-12-31 | −$85.8M | — | — |
Lyell Immunopharma net debt trends
Over the last five fiscal years, Lyell Immunopharma's net debt increased from −$85.8M to −$9.2M, a change of $76.6M. The latest reported quarter, Q2 2026, shows −$26.4M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lyell Immunopharma source filings ↗